Position in CGON
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
-$45,616,320 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
5 quarters on record
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Derivatives in CGON
reported options exposure · as of Jun 30, 2026CallValue
$28,420,000
CallShares
400,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026FARALLON CAPITAL MANAGEMENT LLC holds $7,178,355,833 across 25 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
13,670,881 | $2,537,793,074 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
10,743,063 | $800,143,332 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
6,348,906 | $778,248,897 | |
| 4 | EXEL |
Exelixis, Inc.
|
13,468,010 | $732,794,424 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
14,309,000 | $506,395,510 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
12,277,000 | $383,779,020 | |
| 7 | BEAM |
Beam Therapeutics Inc.
|
10,236,396 | $351,313,110 | |
| 8 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
8,989,098 | $336,372,047 |
All Filings in CGON
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28,420,000 | 400,000 | Call | Other | 2026-08-14 | |
| 2026-03-31 | $45,616,320 | 674,000 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $332,160 | 8,000 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $322,240 | 8,000 | Shares | Other | 2026-02-17 | |
| 2025-06-30 | $208,000 | 8,000 | Shares | Other | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||